Product category:
Chemicals and biochemicals
News Release from: Otava
Edited by the Laboratorytalk Editorial
Team on 20 February 2008
Noteworthy compounds available from
Otava
Otava has extensive experience in the synthesis of highly valuable products for biotech and pharmaceutical applications around the world
Otava sells novel CK2 inhibitors developed by its scientists as well as potent and selective inhibitors of IKK-andepsilon, Sirt1, Sirt2, Stat3, JNK3, GSK-3, CDK9, HDAC, HIF-1, eEF-2 kinase, CFTR chloride channel and more These compounds are available in milligram and gram quantities
This article was originally published on Laboratorytalk on 15 Nov 2005 at 8.00am (UK)
Related stories
cAMP dependent protein kinase focused library
The library was generated using receptor-based virtual screening of the Otava's drug-like Green Collection
It also sells intermediates on route to the synthesis of these compounds.
Custom and bulk quotes for final products and intermediates are available too.
See and download a full list of noteworthy compounds from its website.
Otava helps companies around the world to advance their projects, by synthesising starting materials, intermediates, and/or final products, advanced intermediates in drug synthesis, and combinatorial chemistry templates and building blocks.
Otava's main products and services are compound libraries (about 500,000 in-stock compounds), focused libraries (kinases, proteases, etc), kinase ProHit compound sets, molecular modelling services, custom synthesis on the base of rare scaffolds, anticancer compounds, and contract research.
• Otava: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
